Inhibitory Effect of Coadministration of Silibinin and Cpg-Odn2006 on Metastatic Characteristics (Mmp-2 and Tlr-9) of Hepatocarcinoma Cell Line



Rezaei A¹ ; Saadat F² ; Safavifar F³ ; Berahmeh A⁴ ; Khorramizadeh MR^{5, 6} Show Affiliations
Source: Journal of Mazandaran University of Medical Sciences Published:2019

Abstract

Background and purpose: Hepatocellular carcinoma (HCC) is a most common liver malignancy and Toll-like receptor-9 (TLR9) is essential for CpG DNA-induced immune responses. The aim of this study was to assess the anti-metastatic effects of combined administration of silibinin and CpG-ODN2006 on human hepatocellular carcinoma HepG-2 cell line model. Materials and methods: Inhibitory effects of various concentrations of silibinin and CpG-ODN2006 on HepG-2 cells growth and detection of best dosages for simultaneous usage were assessed by Methylthiazolyldiphenyl-tetrazolium bromide (MTT) method. Expression levels of Matrix Metalloproteinase-2 (MMP2) and TLR9 genes were analyzed by real-time PCR. Gelatin zymography was used to determine the activity of MMP2. Results: Inhibitory effect of coadministration of silibinin (100 μM) and CpG-ODN2006 (100 nM) on HepG-2 cells growth was significant (P<0.05). Real-Time PCR showed no significant differences in cycle threshold of the genes expression analyses (P>0.05). Conclusion: Low dose CpG administration efficiently customized silibinin impact on hepatic cancer. Low doses of the drugs and activating immune mechnasims are definitely preferred, therefore, the co-adminstration of these drugs provide a clear vision for the future of combination therapy. © 2019, Mazandaran University of Medical Sciences. All rights reserved.